New drugs on the horizon for IBD

Digestive Diseases

Volumn 32, Issue , 2014, Pages 74-81

  Sands, Bruce E ^a  

^a MOUNT SINAI HEALTH SYSTEM   (United States)

Author keywords

Biologic therapies; Crohn's disease; IL 12; Leukocyte trafficking; Ulcerative colitis

Indexed keywords

ALPHA4BETA7 INTEGRIN; INFLIXIMAB; INTEGRIN; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT;

ADAPTIVE IMMUNITY; ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; ULCERATIVE COLITIS; ANIMAL; DRUG EFFECTS; GASTROINTESTINAL TRACT; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; LEUKOCYTES; SIGNAL TRANSDUCTION;

EID: 84919822517     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000367832     Document Type: Article

References (27)

1. Turner D, Lev-Tzion R: Understanding Infliximab in Crohn's disease: the long-term outcomes. Dig Dis Sci 2013; 58: 604-607.
2. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration - the multistep paradigm. Cell 1994; 76: 301-314.
3. Hesterberg PE, et al: Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111: 1373-1380.
4. Sandborn WJ, et al: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925.
5. Targan SR, et al: Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007; 132: 1672-1683.
6. Bloomgren G, et al: Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
7. von Andrian UH, Engelhardt B: Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72.
8. Feagan BG, Fox IH, Kishimoto K: Antibody to alpha(4)beta(7) integrin for ulcerative colitis - reply. N Engl J Med 2005; 353: 1180-1181.
9. Feagan BG, et al: Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-1377.
10. Feagan BG, et al: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
11. Sandborn WJ, et al: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-721.
12. Sands BE, et al: Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment had failed. Gastroenterology 2014; 147: 618-627.
13. Govani SM, Waljee AK, Higgins PD: Antiadhesion therapies and the rule of 3 for rare events. Am J Gastroenterol 2013; 108: 1831-1832.
14. Milch C, et al: Vedolizumab, a monoclonal antibody to the gut homing α 4 β 7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 2013; 264: 123-126.
15. Allavena R, et al: CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010; 176: 556-562.
16. Haanstra KG, et al: Antagonizing the α 4 β 1 integrin, but not α 4 β 7 , inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol 2013; 190: 1961-1973.
17. Pan WJ, et al: Pharmacology of AMG 181, a human anti-α 4 β 7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol 2013; 169: 51-68.
18. Vermeire S, et al: The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011; 60: 1068-1075.
19. Vermeire S, et al: Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014; 384: 309-318.
20. Keshav S, et al: A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. Plos One 2013; 8:e60094.
21. Budarf ML, et al: GWA studies: rewriting the story of IBD. Trends Genet 2009; 25: 137-146.
22. Panaccione R, et al: Briakinumab (anti-interleukin 12/23p40, ABT874) for treatment of Crohn's disease (CD). Am J Gastroenterol 2010; 105:S457-S458.
23. Sandborn WJ, et al: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-1528.
24. Shuai K, Liu B: Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3: 900-911.
25. Sandborn WJ, et al: Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624.
26. Sandborn WJ, et al: Phase 2 randomized study of CP-690,550, an oral janus kinase inhibitor, in active Crohn's disease. Gastroenterology 2011; 140:S124.
27. Ito H, et al: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-996.